A purple and pink letter v on a white background.
August 20, 2019

Stretch Mark Reduction with Venus Viva™ Skin Resurfacing

As an experienced medical aesthetics practitioner, you are likely well aware of the difficulties in effectively treating stretch marks. However, growing demand in this area are making striae alba treatments a potential growth market worth exploring. Fortunately, advances in treatment technology have led to a radio frequency-based aesthetics device with proven results in treating troublesome stretch marks that could set your clinic apart from your top competitors.

Growth Opportunities with Stretch Mark Reduction Treatments

According to recent reports, the global market for stretch mark reduction treatments is expected to grow at a compound annual growth rate of 7.7%, hitting an estimated overall market value of $4.0 billion by 2026. Further, an increased incidence rate of obesity globally, alongside increasing awareness surrounding the possibilities of non-invasive aesthetic treatments that complement a healthy, active lifestyle may further propel demand for stretch mark reduction treatments. The North American market is expected to dominate this area, with more than one-third of the estimated demand for stretch mark reduction treatments.

Further still, Medscape notes an estimated 90% of pregnant women, 70% of adolescent females, and 40% of adolescent males have developed stretch marks, though females are considered nearly three times more likely to develop them. Commonly appearing on the chest, abdomen, flanks, and buttocks, stretch marks can affect patients of any skin type or ethnic background.

For your patients, embarrassment regarding stretch marks can be severe and risk a host of negative consequences on quality of life. In fact, one survey among women found that 81% of those surveyed with stretch marks reported they were self-conscious about them, 69% were eager to have them gone, and 20% admitted they wouldn’t get intimate with partners with the lights on because of their stretch marks. Further, the survey notes that three out of every four women who are pregnant are actively attempting to prevent stretch marks, while 39% admit they immediately began to worry about and dread potential stretch marks once they discovered that they were pregnant. Many pregnant women reported being so concerned that 21% said they had greater anxiety over stretch marks than concerns with breastfeeding.

How to Effectively Treat Striae Alba with Venus Viva™ Skin Resurfacing

So, it’s clear that the demand for effective stretch mark reduction treatments is high, so how can your medical aesthetics clinic help?

Stretch marks start out as reddish lesions, called striae rubra, that can develop into more permanent, white lesions, called striae alba, over time. While stretch marks are the result of the progressive and often rapid stretching of the skin’s connective tissue, often associated with weight gain or growth in that area of the body, the precise cause is not well understood. Significant results have been reported using Venus Viva™, the industry’s most customizable skin resurfacing device powered by NanoFractional Radio Frequency (RF) with SmartScan™ technology that offers full operator control of ablation, coagulation, and resurfacing for optimal efficacy. Treatments are safe for all skin types with low downtime.

One published clinical study supports the effectiveness of Venus Viva™ in particular for treating stretch marks utilizing the NanoFractional RF™ applicator with SmartScan™ technology. In this study, patients with Fitzpatrick skin types III and IV presenting with striae alba on the thighs, abdomen, or buttocks received three Venus Viva™ treatments at four-week intervals. Four weeks after the final treatment, surface area, length, and width of the treated striae alba significantly decreased from the baseline (p < 0.001), with patient satisfaction scores regarding improvements in texture, size, and overall appearance reported at 96.67%, 93.94%, and 96.97%, respectively.

Satisfaction ratings from participating physicians reported a minimum 50% improvement in 69.7% of patients. Furthermore, the incidence of post-inflammatory hyperpigmentation (PIH) in this study was lower than that reported in studies using fractional CO 2 lasers (81.2%) and fractional Erbium glass lasers (36.4%). Further, the significant induction of dermal collagen and elastin production was observed in all patients, concluding Venus Viva™’s NanoFractional RF™ technology is highly effective and recommended for the safe treatment of striae alba via skin resurfacing.

Interested in learning more about the technology behind this device or how to increase your practice revenue with Venus Viva™ for the treatment of stretch marks? Contact an expert today using the button below.   

By Yoni Nowmalki July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.